5AM Venture Management LLC Sells 203,908 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

5AM Venture Management LLC decreased its position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 16.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,027,711 shares of the company's stock after selling 203,908 shares during the quarter. Dianthus Therapeutics comprises about 5.3% of 5AM Venture Management LLC's holdings, making the stock its 6th largest position. 5AM Venture Management LLC owned 3.47% of Dianthus Therapeutics worth $22,404,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of DNTH. R Squared Ltd purchased a new position in shares of Dianthus Therapeutics in the 4th quarter worth about $26,000. KLP Kapitalforvaltning AS acquired a new stake in Dianthus Therapeutics in the fourth quarter valued at $33,000. KBC Group NV bought a new position in Dianthus Therapeutics during the 4th quarter valued at $35,000. AlphaQuest LLC grew its holdings in Dianthus Therapeutics by 273.1% during the 4th quarter. AlphaQuest LLC now owns 4,197 shares of the company's stock worth $91,000 after acquiring an additional 3,072 shares in the last quarter. Finally, Intech Investment Management LLC bought a new stake in shares of Dianthus Therapeutics in the 4th quarter worth about $201,000. 47.53% of the stock is owned by hedge funds and other institutional investors.

Dianthus Therapeutics Stock Performance

Shares of Dianthus Therapeutics stock traded down $0.03 during trading on Wednesday, hitting $19.92. 67,053 shares of the stock were exchanged, compared to its average volume of 264,185. Dianthus Therapeutics, Inc. has a 12 month low of $13.37 and a 12 month high of $32.27. The stock's fifty day moving average is $19.85 and its 200 day moving average is $22.57. The stock has a market cap of $639.92 million, a PE ratio of -8.00 and a beta of 1.48.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its quarterly earnings results on Tuesday, March 11th. The company reported ($0.81) EPS for the quarter, beating the consensus estimate of ($0.85) by $0.04. The company had revenue of $1.33 million for the quarter, compared to analyst estimates of $1.40 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. Sell-side analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

DNTH has been the subject of a number of research reports. HC Wainwright reiterated a "buy" rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Wedbush reiterated an "outperform" rating and issued a $36.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Finally, Guggenheim reaffirmed a "buy" rating and issued a $84.00 price objective on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $54.33.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.